Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International : - Premium potential

06/11/2021 | 03:31am EDT

With Biovica offering significant upside potential over the next 6 to 18 months, Redeye raises our base case fair value to SEK 95 (46). DiviTum’s FDA approval will reduce risk and bring commercial clinical sales, while subsequent private use and public reimbursement should propel volumes and clinical support. In addition, the case is bolstered by potential expansion beyond the core market of advanced metastatic breast cancer (mBC).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

© Modular Finance, source Nordic Press Releases

All news about BIOVICA INTERNATIONAL AB (PUBL)
07/30BIOVICA INTERNATIONAL : Notice of annual general meeting in Biovica Internationa..
AQ
06/30BIOVICA INTERNATIONAL AB : – Annual report for the financial year 2020/202..
AQ
06/17BIOVICA INTERNATIONAL : Year-end Report February-April 2020/2021
AQ
06/17Biovica International AB Publ Reports Earnings Results for the Fourth Quarter..
CI
06/11BIOVICA INTERNATIONAL : - Premium potential
AQ
05/22BIOVICA INTERNATIONAL : Capital Markets Day invitation June 9
AQ
05/20BIOVICA INTERNATIONAL : DiviTumTKa shows strong capabilities in malignant melano..
AQ
05/20Biovica’S Divitumtka Shows Strong Capabilities in Malignant Melanoma
CI
04/29BIOVICA INTERNATIONAL : strengthens the management team
AQ
04/29Biovica Announces Management Appointments
CI
More news
Financials
Sales 2022 39,0 M 4,53 M 4,53 M
Net income 2022 -28,0 M -3,26 M -3,26 M
Net cash 2022 90,0 M 10,5 M 10,5 M
P/E ratio 2022 -59,1x
Yield 2022 -
Capitalization 1 662 M 193 M 193 M
EV / Sales 2022 40,3x
EV / Sales 2023 23,6x
Nbr of Employees 20
Free-Float 41,9%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Last Close Price 58,50 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors